December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
IgG Response Against Melanocyte-specific Antigen in Patients With Vogt-Koyanagi-Harada Disease
Author Affiliations & Notes
  • S Otani
    Ophthalmology Tokyo Medical University Shinjuku-ku Tokyo Japan
  • T Sakurai
    Division of Cellular Signaling Institute for Advanced Medical Research Keio University School of Medicine Shinjuku-ku Tokyo Japan
  • M Takeuchi
    Ophthalmology Tokyo Medical University Shinjuku-ku Tokyo Japan
  • Y Goto
    Division of Cellular Signaling Institute for Advanced Medical Research Keio University School of Medicine Shinjuku-ku Tokyo Japan
  • T Fujita
    Division of Cellular Signaling Institute for Advanced Medical Research Keio University School of Medicine Shinjuku-ku Tokyo Japan
  • M Usui
    Ophthalmology Tokyo Medical University Shinjuku-ku Tokyo Japan
  • Y Kawakami
    Division of Cellular Signaling Institute for Advanced Medical Research Keio University School of Medicine Shinjuku-ku Tokyo Japan
  • Footnotes
    Commercial Relationships   S. Otani, None; T. Sakurai, None; M. Takeuchi, None; Y. Goto, None; T. Fujita, None; M. Usui, None; Y. Kawakami, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1527. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S Otani, T Sakurai, M Takeuchi, Y Goto, T Fujita, M Usui, Y Kawakami; IgG Response Against Melanocyte-specific Antigen in Patients With Vogt-Koyanagi-Harada Disease . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1527.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Vogt-Koyanagi-Harada (VKH) disease is an idiopathic systemic disorder affecting organs including the uvea where melanocytes are abundantly contained. Previous evidences suggest that development of VKH disease involves an autoimmune process directed against autoantigens associated with melanocytes. In this study, we examined whether IgG antibodies against melanocyte- or melanoma-associated antigens exist in sera of VKH patients. Methods: Sera obtained from 26 VKH patients and 30 healthy donors were evaluated for presence of IgG antibodies against various melanoma antigens including KU-MEL-1 that was a recently isolated melanoma antigen by the SEREX (serological analysis of recombinant cDNA expression libraries) method and preferentially expressed in melanocytes and melanoma cells. The KU-MEL-1 protein was expressed in E.Coli infected with lambda phases containing the full ORF of KU-MEL-1 and transferred to nitrocellulose membranes. Other melanoma antigens were also expressed. The membranes were incubated with sera for 4 h, and then with alkaline phosphatase-conjugated, goat anti-human IgG Fc for 1 hr. Nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate were used for the enzymatic detection. Results: Fifteen of 26 sera obtained from the VKH patients contained IgG specific for KU-MEL-1, while none of sera from healthy individuals did not. Sera from VKH patients didn't react to melanoma antigens including tyrosinase, NY-MEL-1, NY-ESO-1, and SART-1. Significant correlation was not so far observed between the presence of anti-KU-MEL-1 antibody and the evaluated clinical features in the VKH patients. Conclusion: IgG response against KU-MEL-1 that was an intracellular molecule preferentially expressed in melanocytes and melanoma was frequently detected in the patients with VKH disease, suggesting possibly role of CD4+ T cell response against KU-MEL-1 in autoimmune nature of VKH disease.

Keywords: 463 melanocytes • 526 protein purification and characterization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×